Skip to content

Liposomal bupivacaine vs ropivacaine for ultrasound-guided transversus abdominis plane blocks in laparoscopic lower abdominal tumor resection: A prospective randomized trial

Liposomal bupivacaine vs ropivacaine for ultrasound-guided transversus abdominis plane blocks in laparoscopic lower abdominal tumor resection: A prospective randomized trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091811
Enrollment
Unknown
Registered
2024-11-04
Start date
2024-01-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower abdominal tumor

Interventions

Bupivacaine liposome group:Ultrasound guided bilateral TAPB was performed with bupivacaine liposomes
Ropivacaine group:Bilateral ultrasound-guided TAPB was performed with ropivacaine

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing laparoscopic resection of lower abdominal tumors; (2) ASA grade II-III; (3) Age: 18-70 years.

Exclusion criteria

Exclusion criteria: (1) The patient does not agree to participate in the clinical study; (2) The patient has a clear history of opioid tolerance or allergy; (3) The patient has a history of local anesthetic allergy; (4) Previous history of dementia, mental illness or other central nervous system diseases; (5) Have a history of chronic pain or are taking opioids and other analgesics; (6) Patients are generally in poor condition with a history of serious diseases of cardiovascular system, respiratory system, digestive system, urinary system or central nervous system, and may not survive for more than 3 months; (7) The patient had any of the following conditions in the 12 months before surgery: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism; (8) Pregnant women; (9) Unable to cooperate with follow-up or poor compliance; (10) Patients with acute myocardial infarction, cardiac arrest or shock during surgery or hospitalization; (11) ASA score above grade III.

Design outcomes

Primary

MeasureTime frame
Postoperative opioid use;

Secondary

MeasureTime frame
Postoperative pain score;Postoperative adverse reactions;

Countries

China

Contacts

Public ContactJingdun Xie

Sun Yat-Sen University Cancer Center

xiejd@sysucc.org.cn+86 135 6038 0116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026